COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Intravenous Immunoglobulins for the Treatment of Covid-19 Patients: a Clinical Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04548557
Recruitment Status : Not yet recruiting
First Posted : September 14, 2020
Last Update Posted : September 14, 2020
University of Lahore
Amson Vaccine and Pharma (Pvt) Limited
Information provided by (Responsible Party):
Prof. Dr. Fridoon Jawad Ahmad, University of Health Sciences Lahore

Tracking Information
First Submitted Date  ICMJE September 7, 2020
First Posted Date  ICMJE September 14, 2020
Last Update Posted Date September 14, 2020
Estimated Study Start Date  ICMJE September 15, 2020
Estimated Primary Completion Date October 15, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 11, 2020)
  • In hospital days [ Time Frame: 14 days or discharge ]
    total number of days the patient remain in hospital
  • 14 day mortality [ Time Frame: 14 days ]
    mortality if any in the study duration of 14 days
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: September 11, 2020)
  • D-dimers [ Time Frame: 7 days ]
    reduction in D-dimers (< 250 ng/mL)
  • C-reactive protein [ Time Frame: 7 days ]
    reduction in C-Reactive protein (less than 10 mg/L)
  • Oxygen saturation [ Time Frame: 7 days ]
    improvement in oxygen saturation (pulse oximeter readings within range of 95 to 100%)
  • TNF alpha [ Time Frame: 7 days ]
    reduction in TNF alpha after IVIG treatment (upto 8.1 pg/mL)
  • IL-6 [ Time Frame: 7 days ]
    reduction in IL-6 after IVIG treatment
  • Ferritin [ Time Frame: 7 days ]
    reduction in ferritin levels after IVIG treatment
  • Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 14 days ]
    safety and tolerability
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Intravenous Immunoglobulins for the Treatment of Covid-19 Patients: a Clinical Trial
Official Title  ICMJE Intravenous Immunoglobulins for the Treatment of Covid-19 Patients: a Clinical Trial
Brief Summary The current project is based on the immunological studies covering the potential of disease induced immunoglobulins as treatment regime. We would be able to generate the concentrated antibodies specific against coronavirus (Covid-19). These antibodies can be used as serum therapy. Aside from a Covid-19 vaccine, antibodies from recovered patients could provide a short-term "passive immunization" to the disease. Those antibodies can be extracted from the blood serum of surviving patients and then injected into infected people. Passive immunization usually lasts for a few weeks or months, after which those borrowed or donated antibodies, get broken down by the host body within about 30 days. While drugs to treat patients with covid-19, and vaccines to prevent infection are being developed, a fast acting, stopgap serum therapy could be useful as a first aid for high-risk patients.
Detailed Description

Emerging and re-emerging viruses are a significant threat to global public health. Since the end of 2019, Chinese authorities have reported a cluster of human pneumonia cases in Wuhan City, China and the disease was designated as coronavirus disease 2019 (COVID-19). These cases showed symptoms such as fever, dyspnea, and were diagnosed as viral pneumonia. Whole genome sequencing results show the causative agent is a novel coronavirus, which was initially named 2019-nCoV by World Health Organization (WHO). Later the International Committee on Taxonomy of Viruses (ICTV) officially designate the virus as SARS CoV-2 (Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, 2020), although many virologists argue that HCoV-19 is more appropriate . As of 24 February 2020, 79,331 laboratory-confirmed cases have been reported to the WHO globally, with 77,262 cases in China, including 2,595 deaths. In addition, twenty-nine other countries have confirmed imported cases of SARS-CoV-2 infection raising great public health concerns worldwide. SARS-CoV-2 represents the seventh coronavirus that is known to cause human disease. Coronaviruses (CoVs) are a group of large and enveloped viruses with positive sense, single-stranded RNA genomes. Previously identified human CoVs that cause human disease include severe acute respiratory syndrome coronavirus (SARS-CoV), and Middle East respiratory syndrome coronavirus (MERS-CoV) . SARS-CoV and MERS-CoV infection can result in life threatening disease and have pandemic potential. During 2002-2003, SARS-CoV initially emerged in China and swiftly spread to other parts of the world, causing > 8,000 infections and approximately 800 related deaths worldwide. In 2012, MERS-CoV was first identified in the Middle East and then spread to other countries. As of November 2019, a total of 2,494 MERS cases with 858 related deaths have been recorded in 27 countries globally. Notably, new cases of MERS-CoV infecting humans are still being reported recently. Both SARS-CoV and MERS-CoV are zoonotic pathogens originating from animals. Detailed investigations indicate that SARS-CoV is transmitted from civet cats to humans and MERS-CoV from dromedary camels to humans. The source of SARS-CoV-2, however, is still under investigation, but linked to a wet animal market. There is no specific antiviral treatment recommended for COVID-19, and no vaccine is currently available. The treatment is symptomatic, and oxygen therapy represents the major treatment intervention for patients with severe infection. Mechanical ventilation may be necessary in cases of respiratory failure refractory to oxygen therapy, whereas hemodynamic support is essential for managing septic shock. Although no antiviral treatments have been approved, several approaches have been proposed such as lopinavir/ritonavir (400/100 mg every 12 hours), chloroquine (500 mg every 12 hours), and hydroxychloroquine (200 mg every 12 hours). Alpha-interferon (e.g., 5 million units by aerosol inhalation twice per day) is also used. Preclinical studies suggested that remdesivir (GS5734) - an inhibitor of RNA polymerase with in vitro activity against multiple RNA viruses, including Ebola - could be effective for both prophylaxis and therapy of HCoVs infections. This drug was positively tested in a rhesus macaque model of MERS-CoV infection. One dose of 200 mL convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. Despite a lack of completed clinical trials, the FDA has granted this temporary authorization under its Investigational New Drug Applicants (eINDS) exemption, in light of the extent and nature of the current public health threat that COVID-19 represents. A number of pre-clinical and clinical trials around use of plasma from patients who have recovered are underway, however, and there are some promising signs that convalescent plasma could indeed be effective against SARS-CoV-2.

Apart from convalescent plasma, small scale concentrates of immunoglobulins prepared from convalescent plasma collections provide higher potency and greater consistency than individual units. The feasibility of production of large scale of diseases specific immunoglobulins concentrates can considered for longer term, based on the course of epidemic, access to large numbers of suitable plasma collections, and the available infrastructure for manufacturing such products under GMP.

• Convalescent plasma can be used for serum therapy but it has further limitations which include:

  • Separate plasma for separate blood groups: In case of plasma, it seems difficult to arrange the required blood groups separately for serum therapy, while immunoglobulins can be injected randomly to individual of different blood groups.
  • Serum Sickness & Blood Proteins reactogencity: Only 18% of plasma constitutes immunoglobulins required for passive immunization. Remaining portions contain proteins that pose to reactogenicity threat to patient safety.
  • Dose volume: In case of plasma therapy, 200-300ml of plasma required for single patient that depends upon number of recovered patients available. While in case of immunoglobulins used in virus therapy require only 3-5ml per day.
  • Risk of microbial contamination: As most portion of plasma contain proteins and proteins are more prone to contamination risk. It is difficult to handle the serum to maintain its sterility while immunoglobulins are far less prone to sterility issues.
  • Potency: Concentrated immunoglobulins are far more potent as it shows targeted response. In case of plasma, proteins fractions pose a delayed response.
  • Targeted Population: Plasma therapy is subjected to moderate to severe patients specially, while all effected individuals can take benefit of immunoglobulin therapy because dose of immunoglobulins can be controlled.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
one group in conventional with routine therapy and interventional group will receive intravenous immunoglobulin therapy
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Covid19
Intervention  ICMJE Biological: intravenous immunoglobulin therapy
It is passive immunization therapy. Plasma therapy is subjected to moderate to severe patients specially, while all effected individuals can take benefit of immunoglobulin therapy because dose of immunoglobulins can be controlled
Study Arms  ICMJE
  • No Intervention: Control
    They will not receive any intervention
  • Experimental: IVIG group
    They will reveive intravenous immunoglobulin therapy
    Intervention: Biological: intravenous immunoglobulin therapy
Publications *

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: September 11, 2020)
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE November 15, 2020
Estimated Primary Completion Date October 15, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Age > 18 yrs
  • Both genders
  • Lab Confirmed COVID-19 infection by PCR or plasma positive of specific antibody against COVID-19
  • In hospital treatment ≥ 72 hours
  • Admitted patients
  • Mild to moderately severe patients

Exclusion Criteria:

  • Exist of other evidences that can explain pneumonia including but not limited to influenza A virus, influenza B virus, bacterial pneumonia, fungal pneumonia, noninfectious causes, etc.
  • Patients with respiratory diseases other than Covid-19 infection
  • Pregnant and breastfeeding women
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 90 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: riffat mehboob, Ph.D +923313380909
Contact: Fridoon J Ahmad, Ph.D
Listed Location Countries  ICMJE Pakistan
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT04548557
Other Study ID Numbers  ICMJE UniversityHSL-IVIG
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Prof. Dr. Fridoon Jawad Ahmad, University of Health Sciences Lahore
Study Sponsor  ICMJE University of Health Sciences Lahore
Collaborators  ICMJE
  • University of Lahore
  • Amson Vaccine and Pharma (Pvt) Limited
Investigators  ICMJE
Study Chair: Javed Akram, MBBS,FRCP,MRCP Saglik Bilimleri Universitesi
Principal Investigator: Fridoon J Ahmad, Ph.D Saglik Bilimleri Universitesi
PRS Account University of Health Sciences Lahore
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP